Myasthenia Gravis

Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.

It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.


Clinical trials ongoing at the Institute:

  • UCB MG0007 : A Phase 3, open-label extension (OLE) study to evaluate 6-week treatment cycles of rozanolixizumab in study participants with gMG
  • ALX1720: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
  • R3918-MG-2018 : Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
  • MOM-M281-011 : Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis
  • ARGX-113-2003 – ADAPT NXT: A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis
  • MYAPATH: Creation of a collection of biological resources for the study of pathologies that can lead to Myasthenia Gravis



UCB MG0007


Intervention rozanolixizumab ALXN1720
Principal investigator
Sophie Demeret Sophie Demeret
Sponsor UCB Alexion
Study status Ongoing Ongoing
Recruitment status Completed Not started
Population Adult Adult
  + infos on + infos on






ARGX-113-2003 – ADAPT NXT


Intervention pozelimab et cemdisiran nipocalimab Efgartigimod
Principal investigator Sophie Demeret Sophie Demeret Sophie Demeret Anthony Béhin
Sponsor Regeneron Jannsen-Cilag Argenx AIM
Study status In preparation Ongoing Ongoing Ongoing
Recruitment status Not started Ongoing Ongoing Ongoing
Population Adult Adult Adult Adult
  + infos on + infos on + infos on


Contact :